Zafgen Inc. (NASDAQ:ZFGN) shares traded down 2% on Friday . The company traded as low as $2.95 and last traded at $2.98, with a volume of 233,806 shares. The stock had previously closed at $3.04.

A number of research analysts have weighed in on the company. Leerink Swann reissued a “market perform” rating and set a $6.00 price target on shares of Zafgen in a research note on Wednesday, July 20th. Cowen and Company lowered Zafgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 20th. Canaccord Genuity set a $4.00 target price on Zafgen and gave the stock a “hold” rating in a research report on Thursday, July 21st. FBR & Co lowered Zafgen from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $20.00 to $5.00 in a research report on Wednesday, July 20th. Finally, Zacks Investment Research raised Zafgen from a “hold” rating to a “buy” rating and set a $7.25 target price on the stock in a research report on Thursday, May 12th. Five research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Zafgen currently has a consensus rating of “Buy” and an average target price of $14.22.

The company’s 50-day moving average is $3.51 and its 200-day moving average is $5.76. The company’s market cap is $80.62 million.

In other news, insider Thomas E. Hughes acquired 10,000 shares of the stock in a transaction on Monday, August 29th. The shares were purchased at an average cost of $3.00 per share, for a total transaction of $30,000.00. Following the transaction, the insider now owns 63,936 shares in the company, valued at approximately $191,808. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Patricia L. Allen acquired 16,000 shares of the stock in a transaction on Tuesday, July 26th. The shares were purchased at an average price of $3.12 per share, for a total transaction of $49,920.00. The disclosure for this purchase can be found here.

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.